RxDoctor Payments Data

John Fahrenholz, MD

Allergy & Immunology · Nashville, TNNPI 1518958370

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $97,243 of the $124,331 with a category attached, or 78.2%. Blueprint Medicines Corporation accounts for 77.0% of it on its own, with 11 other manufacturers making up the rest. Among allergy & immunology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$124,331in general payments, 2019–2025

Across 163 payments — averaging $762.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Blueprint Medicines Corporation$96K
  • Sanofi US Services Inc.$15K
  • Biocryst Pharmaceuticals, Inc.$7K
  • CSL Behring$4K
  • Tersera Therapeutics LLC$785
  • Novartis$718
  • plus $1K from 6 others

What the payments were for

  • Consulting fees$4,3113%
  • Speaking & faculty fees$97,24378%
  • Travel & lodging$18,27115%
  • Food & beverage$4,4724%
  • Education$340%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$124,331 in reported general payments places this provider in the 90th percentile of 79 allergy & immunology providers in Tennessee.

See all allergy & immunology providers in Tennessee

Medicare billing

Part B allowed, 2024
$142,081
Medicare patients
108
Services billed
3,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab29$105,407
Dupixent PenDupilumab14$52,577
Dupixent SyringeDupilumab14$47,090
Cromolyn Sodium17$14,776
Epinephrine11$3,462
Arnuity ElliptaFluticasone Furoate12$2,447
Tacrolimus12$597
Albuterol Sulfate HfaAlbuterol Sulfate17$503
Montelukast Sodium45$317
Famotidine19$154
Prednisone18$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$609$105,40729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 allergy & immunology providers in Tennessee.

Other allergy & immunology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →